Abstract
HIV-associated hematological abnormalities involve all lineages of blood cells, thus implying that the virus impairs the function of early HSCs. However, the underlying mechanisms of this defect are unknown, particularly since HSCs are largely resistant to HIV-1 infection. In this issue of the JCI, Prost and colleagues show that the viral accessory protein Negative factor (Nef) plays a potentially critical role in the pathogenesis of HIV/SIV-associated hematopoietic dysfunction by affecting the clonogenic potential of HSCs (see the related article beginning on page 1765). Soluble Nef induces PPARγ in uninfected HSCs, thereby suppressing the expression of STAT5A and STAT5B, two factors necessary for proper HSC function. The identification of this novel activity of extracellular Nef defines a new mechanism of HIV/SIV pathogenesis and suggests that approaches aimed at increasing STAT5A and STAT5B expression may be considered in HIV-infected individuals with prominent hematological abnormalities. The results also raise the question of whether dysregulation of hematopoiesis by extracellular Nef plays a role in the development of T cell immunodeficiency and the high levels of chronic immune activation associated with AIDS.
HIV-1 infection causes immunodeficiency by inducing a progressive decline in number of CD4+ helper T cells. However, the mechanisms of HIV/AIDS pathogenesis are complex, as it is still unclear to what extent this progressive CD4+ T cell depletion is caused by direct killing of infected cells or rather by the indirect effects of chronic, generalized immune activation (1). Importantly, HIV infection is also associated with hematopoietic abnormalities characterized by impaired generation and function of cells of all blood lineages (i.e., red blood cells, platelets, and white blood cells). These hematopoietic dysfunctions may cause various levels of cytopenias and also contribute to the development of T cell immunodeficiency (Figure 1) (2). Since all blood cell lineages may be affected, HIV-1 infection apparently deregulates the function of early hematopoietic progenitor cells. This assumption was confirmed by studies showing that CD34+ progenitor cells from HIV-infected patients show reduced growth and differentiation in vitro (3, 4).
HIV-associated hematological abnormalities seem to be dependent on the level of virus replication, as these abnormalities are severe in late-stage AIDS patients with high viremia but can be corrected by highly active antiretroviral therapy (HAART) (5, 6). The mechanisms underlying these hematological abnormalities are still obscure. While HSCs express low levels of CD4 and CCR5, several studies indicate that they are not susceptible to HIV-1 infection (7–9). Alternative mechanisms that were proposed — although without definitive experimental evidence — include an effect of HIV-1 proteins on uninfected HSCs as well as the hematosuppressive potential of certain proinflammatory cytokines that are produced at high levels during HIV infection (10–13).
Impaired STAT5 and HSC function in SIV-infected macaques
The study from Prost and colleagues in this issue of the JCI (14) describes a series of experiments aimed at elucidating the mechanisms causing the hematopoietic abnormalities associated with HIV infection and AIDS. The main conclusion is that the extracellular viral accessory protein Negative factor (Nef) causes hyperactivation of PPARγ, that in turn reduces the expression of the STAT5A/B transcription factors, with consequent functional defects of HSCs (Figure 2). In the first set of experiments, the authors studied SIVmac251-infected macaques and confirmed the existence of three key features of HIV-1–associated defective hematopoiesis: (a) the number of CD34+ HSCs remains normal; (b) the clonogenic potential of these cells declines progressively over the course of infection; and (c) these cells are not infected by the virus. Next, they showed that the HSC defect correlates with low levels of STAT5A and STAT5B expression and, importantly, that overexpression of STAT5B in CD34+ cells by a lentiviral vector rescues the clonogenic function. The role of STAT5A/B in regulating the proliferation, differentiation, and survival of HSCs is well established (15), and the current results reported by Prost and colleagues are consistent with data from murine models showing that knockdown of either STAT5A or STAT5B causes anemia and erythroid defects (16), whereas double knockout of STAT5A and STAT5B proves to be highly anemic in utero and perinatally lethal (17).
A role for Nef in impaired hematopoiesis
Surprisingly, the Prost study (14) shows that extracellular, soluble forms of the HIV and SIVmac Nef proteins may downmodulate STAT5 expression by activating the transcriptional suppressor PPARγ, thus providing a new mechanism to explain the HIV-associated HSC defects (Figure 2B). Of note, this inhibitory effect of soluble Nef on the clonogenic potential of progenitor cells (which the authors elegantly map to a central region of HIV-1 Nef between amino acids 66 and 97) might explain why the hematological abnormalities of HIV-infected patients are correlated with disease progression even though HSCs are not directly infected by the virus. Nef is an early accessory protein of immunodeficiency viruses that is required for efficient viral persistence and strongly accelerates disease progression in HIV-1–infected humans and in experimentally SIV-infected rhesus macaques (18). Nef performs a striking variety of activities that allow the virus to spread efficiently in the infected host and to evade the immune system, including downmodulation of CD4, MHC class I, and in many cases CD3 (most SIV strains and HIV-2, but not HIV-1 and its simian precursors), upregulation of the invariant chain associated with immature MHC class II complexes, and enhancement of viral infectivity and replication (18, 19). Furthermore, Nef interacts with various kinases, modulates cell signaling pathways, and might alter cytokine secretion (20). All these activities of Nef require an intact N-terminal myristoylation signal and are exerted within the virally infected cell. However, Nef is also found in the extracellular environment and reaches concentrations of up to 10 ng/ml in sera of HIV-1–infected individuals (21). Reported effects of extracellular Nef include activation of STAT1 and STAT3 in macrophages (22), induction of apoptosis (23), and immunoglobulin class switching in bystander B cells (24). However, the true in vivo significance of these findings is difficult to assess as the above mentioned results were often obtained using rather artificial experimental conditions characterized by exceptionally high levels of Nef usually produced by bacteria. In this regard, Prost and coworkers (14) demonstrate that sera from SIVmac251-infected macaques can directly suppress STAT5A/B expression and cause HSC dysfunction (and that these effects are reduced by anti-Nef antibodies). These latter results not only support the possibility that the Nef-dependent STAT5A/B suppression occurs at “physiologic” concentrations of this protein, but also raise the question of whether humoral immune responses to Nef, which are detectable in the majority of HIV-1–infected individuals (25), may prevent the development of hematopoietic dysfunction.
Nef-mediated suppression of hematopoiesis: viral immune evasion strategy or suboptimal virus-host adaptation?
As mentioned above, the current study (14) might explain why the severity of the hematologic abnormalities correlates with the levels of virus replication and why functional hematopoiesis is restored by HAART. The observation that extracellular Nef impairs the function of CD34+ progenitor cells in trans also clarifies why HIV-1 does not need to directly infect HSCs to cause hematological abnormalities. However, new interesting questions are raised by the observed results. For example, Prost et al. show that peptides corresponding to residues 66–97 of the central core region of HIV-1 Nef are sufficient to reproduce the defect of HSC function. Although this region is relatively well conserved, the HIV-1 and SIVmac251 Nef sequences differ in 9 of the 31 amino acid residues. Those of other SIVs are frequently even more divergent and — in contrast to HIV-1 Nef proteins — often do not contain an intact Src homology 3–binding (SH3-binding) domain in this region, raising the question of whether this Nef activity is conserved among the different groups of primate lentiviruses. This question is crucial as SIV infection of natural hosts such as the Sooty mangabeys or African green monkeys is not associated with immunodeficiency or impaired bone marrow function despite chronically high levels of virus replication (26). From this perspective, it will be interesting to elucidate whether this effect of Nef is mainly an indicator of suboptimal virus-host adaptation in the evolutionarily recent human and experimental rhesus macaque hosts or indeed a conserved strategy of primate lentiviruses to evade the host immune system by suppressing the clonogenic potential of HSCs.
Perspectives
While the current study by Prost and colleagues (14) is of great interest, much work will be required to define the mechanism by which extracellular Nef induces PPARγ and to determine whether the levels of Nef in blood and bone marrow are sufficient to impair HSC function during HIV infection. It will also be important to better understand (a) to what extent this impaired hematopoiesis contributes to the T cell immunodeficiency associated with progression to AIDS, and (b) how these hematological defects relate to the state of chronic hyperimmune activation that seems to drive the loss of CD4+ T cells and progression to immunodeficiency in HIV-infected individuals. As STAT5 signaling plays a critical role in T cell development and function (27), an additional question is whether Nef also affects T cell homeostasis by suppressing STAT5A/B function in other, more mature T cell subsets (28). From a clinical point of view, the results of Prost and colleagues may potentially identify Nef and/or PPARγ as target for new therapeutic approaches aimed at preventing or correcting the hematologic abnormalities associated with HIV-1 infection. On the other hand, the identification of PPARγ as a suppressor of HSC function might have implications for the use of PPARγ agonists, such as glitazones, in the treatment of diabetes.
Acknowledgments
F. Kirchhoff thanks the Wilhelm-Sander Foundation, the Deutsche Forschungsgemeinschaft, and the NIH (R01AI067057) for support.
Footnotes
Nonstandard abbreviations used: Nef, Negative factor.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 118:1622–1625 (2008). doi:10.1172/JCI35487.
See the related article beginning on page 1765.
References
- 1.Sodora D.L., Silvestri G. Immune activation and AIDS pathogenesis. AIDS. 2008;22:439–446. doi: 10.1097/QAD.0b013e3282f2dbe7. [DOI] [PubMed] [Google Scholar]
- 2.Moses A., Nelson J., Bagby G.C., Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 1998;91:1479–1495. [PubMed] [Google Scholar]
- 3.Marandin A., et al. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood. 1996;88:4568–4578. [PubMed] [Google Scholar]
- 4.Sloand E.M., et al. Secondary colony formation after long-term bone marrow culture using peripheral blood and bone marrow of HIV-infected patients. AIDS. 1997;11:1547–1553. doi: 10.1097/00002030-199713000-00002. [DOI] [PubMed] [Google Scholar]
- 5.Isgrò A., et al. Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses. 2000;16:1471–1479. doi: 10.1089/088922200750005994. [DOI] [PubMed] [Google Scholar]
- 6.Baillou C., et al. Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood stem cell-based gene therapy. AIDS. 2003;17:563–574. doi: 10.1097/00002030-200303070-00012. [DOI] [PubMed] [Google Scholar]
- 7.Koka P.S., Jamieson B.D., Brooks D.G., Zack J.A. Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J. Virol. 1999;73:9089–9097. doi: 10.1128/jvi.73.11.9089-9097.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Weichold F.F., et al. Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood. 1998;91:907–915. [PubMed] [Google Scholar]
- 9.Zhang J., Scadden D.T., Crumpacker C.S. Primitive hematopoietic cells resist HIV-1 infection via p21. J. Clin. Invest. 2007;117:473–481. doi: 10.1172/JCI28971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Calenda V., Graber P., Delamarter J.F., Chermann J.C. Involvement of HIV nef protein in abnormal hematopoiesis in AIDS: in vitro study on bone marrow progenitor cells. Eur. J. Haematol. 1994;52:103–107. doi: 10.1111/j.1600-0609.1994.tb01294.x. [DOI] [PubMed] [Google Scholar]
- 11.Reinhold D., Wrenger S., Kahne T., Ansorge S. HIV-1 Tat: immunosuppression via TGF-beta1 induction. Immunol. Today. 1999;20:384–385. doi: 10.1016/s0167-5699(99)01497-8. [DOI] [PubMed] [Google Scholar]
- 12.Sugiura K., Oyaizu N., Pahwa R., Kalyanaraman V.S., Pahwa S. Effect of human immunodeficiency virus-1 envelope glycoprotein on in vitro hematopoiesis of umbilical cord blood. Blood. 1992;80:1463–1469. [PubMed] [Google Scholar]
- 13.Maciejewski J.P., Weichold F.F., Young N.S. HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. J. Immunol. 1994;153:4303–4310. [PubMed] [Google Scholar]
- 14.Prost S., et al. Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARγ/STAT5 signaling pathway in macaques. J. Clin. Invest. 2008;118:1765–1775. doi: 10.1172/JCI33037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bunting K.D. STAT5 signaling in normal and pathologic hematopoiesis. Front. Biosci. 2007;12:2807–2820. doi: 10.2741/2274. [DOI] [PubMed] [Google Scholar]
- 16.Socolovsky M., Fallon A.E., Wang S., Brugnara C., Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in Stat5a–/–5b–/– mice: a direct role for Stat5 in Bcl-X(L) induction. . Cell. 1999;98:181–191. doi: 10.1016/S0092-8674(00)81013-2. [DOI] [PubMed] [Google Scholar]
- 17.Cui Y., et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 2004;24:8037–8047. doi: 10.1128/MCB.24.18.8037-8047.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Foster J.L., Garcia J.V. Role of Nef in HIV-1 replication and pathogenesis. Adv. Pharmacol. 2007;55:389–409. doi: 10.1016/S1054-3589(07)55011-8. [DOI] [PubMed] [Google Scholar]
- 19.Schindler M., et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006;125:1055–1067. doi: 10.1016/j.cell.2006.04.033. [DOI] [PubMed] [Google Scholar]
- 20.Renkema G.H., Saksela K. Interactions of HIV-1 NEF with cellular signal transducing proteins. . Front. Biosci. 2000;5:D268–D283. doi: 10.2741/Renkema. [DOI] [PubMed] [Google Scholar]
- 21.Fujii Y., Otake K., Tashiro M., Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett. 1996;393:93–96. doi: 10.1016/0014-5793(96)00859-9. [DOI] [PubMed] [Google Scholar]
- 22.Federico M., et al. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood. 2001;98:2752–2761. doi: 10.1182/blood.V98.9.2752. [DOI] [PubMed] [Google Scholar]
- 23.Okada H., Takei R., Tashiro M. HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). FEBS Lett. 1997;414:603–606. doi: 10.1016/S0014-5793(97)01080-6. [DOI] [PubMed] [Google Scholar]
- 24.Qiao X., et al. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat. Immunol. 2006;7:302–310. doi: 10.1038/ni1302. [DOI] [PubMed] [Google Scholar]
- 25.Cheingsong-Popov R. Antibodies to HIV-1 nef (p27): prevalence, significant and relationship to seroconversion. AIDS Res. Hum. Retroviruses. 1990;6:1099–1105. doi: 10.1089/aid.1990.6.1099. [DOI] [PubMed] [Google Scholar]
- 26.Silvestri G., Paiardini M., Pandrea I., Lederman M.M., Sodora D.L. Understanding the benign nature of SIV infection in natural hosts. . J. Clin. Invest. 2007;117:3148–3154. doi: 10.1172/JCI33034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Burchill M.A., Yang J., Vang K.B., Farrar M.A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol. Lett. 2007;114:1–8. doi: 10.1016/j.imlet.2007.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ye P., Kirschner D.E., Kourtis A.P. The thymus during HIV disease: role in pathogenesis and in immune recovery. Curr. HIV Res. 2004;2:177–183. doi: 10.2174/1570162043484898. [DOI] [PubMed] [Google Scholar]